Order-made Medical Research Inc.

Order-made Medical Research Inc. (President: Yasufumi Murakami, HQs: Kashiwa City, Chiba, hereinafter referred to as “OMR”), Mitsubishi Tanabe Pharma Corporation (President: Masayuki Mitsuya, HQs: Osaka City, hereinafter referred to as "Mitsubishi Tanabe Pharma" ), and Trans Chromosomics, Inc. (President: Mitsuo Oshimura, HQs: Yonago, Tottori, hereinafter referred to as "TC") are pleased announce that three of companies executed a Joint Research Agreement on on therapeutic antibodies for neurodegenerative diseases treatment including amyotrophic lateral sclerosis (ALS) in November, 2017.

​

OMR is working on R&D for therapeutic antibodies against target molecules that were difficult to discover using unique antibody engineering technology " LIMAXYS TM ". TC possesses fully human antibody-producing animals using its own artificial chromosome technology and cell evaluation method concerning neurodegenerative diseases. Mitsubishi Tanabe Pharma is conducting edaravone (trade name: Radicat (Japan), Radicava (USA)), which has been used as a therapeutic agent in the acute phase of cerebral infarction, in Japan in June 2015, and additionally obtained approval for efficacy/effect as " Suppression of the progression of functional disorder of Amyotrophic Lateral Sclerosis ", and then FDA approved ALS as an indication in the United States in May 2017.

​

Please refer to this press release released by Mitsubishi Tanabe Pharma.

https://www.mt-pharma.co.jp/shared/show.php?url=../release/nr/2017/MTPC171213.html